• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Slovakia Pharmaceuticals and Healthcare Report Q2 2008 - Product Image

Slovakia Pharmaceuticals and Healthcare Report Q2 2008

  • ID: 604167
  • April 2008
  • Region: Slovakia
  • 59 pages
  • Business Monitor International


  • Biotika
  • GlaxoSmithKline (GSK)
  • Hoechst-Biotika
  • Imuna Pharma
  • Merck & Co
  • Novartis
  • MORE

The Slovakia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Slovakias pharmaceuticals and healthcare industry.

Slovakian pharmaceutical market remains one of the less attractive markets amongst its Central and Eastern European (CEE) peers, primarily due to its small size and a sizeable healthcare debt, despite a relatively favourable business environment. However, the new left-leaning government, elected in 2006, has passed a basket of measures in an attempt to achieve a better financial balance, although some of the changes have been strongly opposed. Most recently, the government banned profit-making in the healthcare insurance sector, with the aim of freeing up more funds for patients’ needs, but also disincentivising the companies in the sector by removing competition and essentially their reason for operating.

In terms of market segmentation, the generics market represents around a quarter of the total by value. However, the new anti-Bolar (and thus anti-EU legislation) law threatens to delay the entry of copy products onto the market over the coming years, to the detriment of the local as well as international READ MORE >


  • Biotika
  • GlaxoSmithKline (GSK)
  • Hoechst-Biotika
  • Imuna Pharma
  • Merck & Co
  • Novartis
  • MORE

Executive Summary
Slovakia Pharmaceuticals Industry SWOT
Slovakia Political SWOT
Slovakia Economicsl SWOT
Slovakia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Pharmaceutical Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Slovakia - Pharmaceutical Market Summary
Regulatory Regime
Generics Legislation
Recent Regulatory Developments
Intellectual Property Regime
IP Deficiencies
Pricing Regime
Reimbursement Regime
Pricing Developments
Industry Trends And Developments
Health Status
Table: Main Causes Of Mortality And Morbidity In Slovakia, 2006
Healthcare Sector
Healthcare Sector Reforms
Health Insurance
Recent Health Insurance Developments
Healthcare Funding Crisis
Pharmaceutical Industry
Research And Development
Company Developments
Medical Devices
Industry Forecast Sce
Overall Market Forecast
Table: Drug Expenditure and Prescription Market Indicators (US$mn unless otherwise stated)
Industry Forecast
Table: Health Market Indicators
Key Growth Factors - Macroeconomic
Table: Slovakia - Economic Activity
Patented Market Forecast
Table Patented Market Indicators
Generics Market Forecast
Table: Generic Market Indicators
OTC Market Forecast
Table: OTC Market Indicators (US$mn unless otherwise stated)
Export/Import Forecasts
Table: Trade balance Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Healthcare Market Indicators
Key Risks To our Forecast Scenario
Competitive Landscape
Table Competitive Landscape in Slovakia
Company Monitor
GlaxoSmithKline (GSK)
Merck & Co
Indigenous Manufacturers
Zentiva (incorporating Sicomed)
Imuna Pharma
Our Forecast Modelling

How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

- Biotika
- GlaxoSmithKline (GSK)
- Hoechst-Biotika
- Imuna Pharma
- Merck & Co
- Novartis
- Pfizer
- Roche
- Sanofi-Aventis
- Zentiva (incorporating Sicomed)

Note: Product cover images may vary from those shown



Our Clients

Our clients' logos